553 related articles for article (PubMed ID: 34728538)
1. SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis.
Yokoyama S; Takahashi A; Kikuchi R; Nishibu S; Lo JA; Hejna M; Moon WM; Kato S; Zhou Y; Hodi FS; Song JS; Sakurai H; Fisher DE; Hayakawa Y
Cancer Res; 2021 Dec; 81(24):6131-6141. PubMed ID: 34728538
[TBL] [Abstract][Full Text] [Related]
2. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Garcia-Diaz A; Shin DS; Moreno BH; Saco J; Escuin-Ordinas H; Rodriguez GA; Zaretsky JM; Sun L; Hugo W; Wang X; Parisi G; Saus CP; Torrejon DY; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Damoiseaux R; Lo RS; Ribas A
Cell Rep; 2017 May; 19(6):1189-1201. PubMed ID: 28494868
[TBL] [Abstract][Full Text] [Related]
3. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF
Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655
[TBL] [Abstract][Full Text] [Related]
5. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
6. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling.
Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I
Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal regulation of the Il9 locus by counteracting activities of transcription factors IRF1 and IRF4.
Campos Carrascosa L; Klein M; Kitagawa Y; Lückel C; Marini F; König A; Guralnik A; Raifer H; Hagner-Benes S; Rädler D; Böck A; Kang C; Lohoff M; Garn H; Schaub B; Berberich-Siebelt F; Sakaguchi S; Bopp T; Huber M
Nat Commun; 2017 May; 8():15366. PubMed ID: 28497800
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization.
Liu N; Zhang J; Yin M; Liu H; Zhang X; Li J; Yan B; Guo Y; Zhou J; Tao J; Hu S; Chen X; Peng C
Mol Ther; 2021 Jul; 29(7):2321-2334. PubMed ID: 33744468
[TBL] [Abstract][Full Text] [Related]
9. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects.
Rosenbaum SR; Tiago M; Caksa S; Capparelli C; Purwin TJ; Kumar G; Glasheen M; Pomante D; Kotas D; Chervoneva I; Aplin AE
Cell Rep; 2021 Dec; 37(10):110085. PubMed ID: 34879275
[TBL] [Abstract][Full Text] [Related]
10. The miR-31-SOX10 axis regulates tumor growth and chemotherapy resistance of melanoma via PI3K/AKT pathway.
Zheng Y; Sun Y; Liu Y; Zhang X; Li F; Li L; Wang J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2451-2458. PubMed ID: 29969627
[TBL] [Abstract][Full Text] [Related]
11. Identification of STXBP6-IRF1 positive feedback loop in regulation of PD-L1 in cancer.
Liu Y; Huang Z; Wei Y; Zhang M; Li X; Yang S; Wang H
Cancer Immunol Immunother; 2021 Feb; 70(2):275-287. PubMed ID: 32700091
[TBL] [Abstract][Full Text] [Related]
12. SOX10 Inhibits T Cell Recognition by Inducing Expression of the Immune Checkpoint Molecule PD-L1 in A375 Melanoma Cells.
Sasaki K; Hirohashi Y; Murata K; Minowa T; Nakatsugawa M; Murai A; Mizue Y; Kubo T; Kanaseki T; Tsukahara T; Iwabuchi S; Hashimoto S; Uhara H; Ishida-Yamamoto A; Torigoe T
Anticancer Res; 2023 Apr; 43(4):1477-1484. PubMed ID: 36974807
[TBL] [Abstract][Full Text] [Related]
13. KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.
Yoshino H; Sato Y; Nakano M
Curr Issues Mol Biol; 2021 May; 43(1):153-162. PubMed ID: 34069326
[TBL] [Abstract][Full Text] [Related]
14. MEK1/2 Inhibitors Unlock the Constrained Interferon Response in Macrophages Through IRF1 Signaling.
Yang L; Ding JL
Front Immunol; 2019; 10():2020. PubMed ID: 31507609
[TBL] [Abstract][Full Text] [Related]
15. miR-146a Controls Immune Response in the Melanoma Microenvironment.
Mastroianni J; Stickel N; Andrlova H; Hanke K; Melchinger W; Duquesne S; Schmidt D; Falk M; Andrieux G; Pfeifer D; Dierbach H; Schmitt-Graeff A; Meiss F; Boerries M; Zeiser R
Cancer Res; 2019 Jan; 79(1):183-195. PubMed ID: 30425059
[TBL] [Abstract][Full Text] [Related]
16. Cooperative contributions of interferon regulatory factor 1 (IRF1) and IRF8 to interferon-γ-mediated cytotoxic effects on oligodendroglial progenitor cells.
Horiuchi M; Itoh A; Pleasure D; Ozato K; Itoh T
J Neuroinflammation; 2011 Jan; 8():8. PubMed ID: 21261980
[TBL] [Abstract][Full Text] [Related]
17. Sox10 regulates skin melanocyte proliferation by activating the DNA replication licensing factor MCM5.
Su Z; Zheng X; Zhang X; Wang Y; Zhu S; Lu F; Qu J; Hou L
J Dermatol Sci; 2017 Mar; 85(3):216-225. PubMed ID: 27955842
[TBL] [Abstract][Full Text] [Related]
18. A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma.
van Duijn A; Willemsen KJ; van Uden NOP; Hoyng L; Erades S; Koster J; Luiten RM; Bakker WJ
Cancer Immunol Immunother; 2022 Mar; 71(3):529-540. PubMed ID: 34268602
[TBL] [Abstract][Full Text] [Related]
19. SOX10, a novel HMG-box-containing tumor suppressor, inhibits growth and metastasis of digestive cancers by suppressing the Wnt/β-catenin pathway.
Tong X; Li L; Li X; Heng L; Zhong L; Su X; Rong R; Hu S; Liu W; Jia B; Liu X; Kou G; Han J; Guo S; Hu Y; Li C; Tao Q; Guo Y
Oncotarget; 2014 Nov; 5(21):10571-83. PubMed ID: 25301735
[TBL] [Abstract][Full Text] [Related]
20. SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis.
Gao K; Shi Q; Gu Y; Yang W; He Y; Lv Z; Ding Y; Cao W; Wang C; Wan X
Cell Death Differ; 2023 Feb; 30(2):475-487. PubMed ID: 36481790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]